论文部分内容阅读
目的:探讨米索前列醇用于足月妊娠引产的有效性和安全性。方法:米索前列醇组:有引产指征、无引产及使用米索前列醇禁忌证的单胎、头位、胎膜完整的足月妊娠妇女62例,采用米索前列醇阴道给药引产,间隔4h重复给药,24h最大剂量为200μg。缩宫素组:同条件足月妊娠妇女62例,采用小剂量缩宫素静脉滴注引产。结果:米索前列醇组和缩宫素组引产成功率分别为93.6%和85.4%,有统计学差异(P<0.05)。结论:米索前列醇用于足月妊娠引产是有效而且安全的方法,其引产成功率和缩短引产时间方面优于小剂量缩宫素静脉滴注引产。
Objective: To investigate the efficacy and safety of misoprostol for induction of labor during term pregnancy. Methods: Misoprostol group: there are 62 cases of single-term, head position, full-term pregnancy women without induced labor and contraindication of misoprostol, vaginal administration of misoprostol induced labor , Repeated intervals of 4h, 24h maximum dose of 200μg. Oxytocin group: 62 cases of women with the same conditions of full-term pregnancy, a small dose of oxytocin intravenous drip induction. Results: The success rates of misoprostol and oxytocin were 93.6% and 85.4%, respectively, with statistical significance (P <0.05). Conclusions: Misoprostol is an effective and safe method for induction of labor during term pregnancy. Its success rate of induction and shortening the induction time are better than intravenous oxytocin in small doses.